MSC Exosomes for Crohn’s Disease & IBD
Mesenchymal stem cell (MSC)-derived exosomes are studied in regenerative research for Crohn’s disease and inflammatory bowel disease (IBD). This overview is provided for research and educational purposes only.
What MSC exosomes are
MSC-derived exosomes are nanoscale, cell-free extracellular vesicles (roughly 30–150 nm) that carry signaling cargo such as proteins, lipids, and microRNA. They are not stem cells, and BioRegenEx supplies them as characterized, research-use-only material with per-lot documentation.
What the research explores
In preclinical colitis and Crohn’s models, MSC-derived exosomes have been studied for signaling related to mucosal healing, macrophage polarization, and intestinal inflammation (via microRNA cargo such as miR-34a-5p and miR-21-5p). These are research findings only. The studies are indexed in our Exosome Research Library under Gut & IBD.
Why sourcing and characterization matter
Because exosome composition depends on the source cells and manufacturing, research-grade material is defined by measurement — particle size and concentration, sterility and endotoxin screening, and a per-lot Certificate of Analysis.
Frequently Asked Questions
Are MSC exosomes an approved IBD treatment?
No. MSC-derived exosomes are not FDA-approved to treat this or any condition and are supplied for research use only (RUO).
What does the research focus on?
Preclinical research focuses on mucosal healing and anti-inflammatory immune signaling.
For research and educational purposes; research-use-only.
These statements have not been evaluated by the FDA. BioRegenEx supplies MSC-derived exosomes for research use only (RUO); they are not intended to diagnose, treat, cure, or prevent any disease. This content is educational and is not medical advice.